Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Repositioning Therapeutics for COVID-19: Virtual Screening of the Potent Synthetic and Natural Compounds as SARS-CoV-2 3CLpro Inhibitors
Sattari et al., Research Square, doi:10.21203/rs.3.rs-37994/v1 (Preprint)
Sattari et al., Repositioning Therapeutics for COVID-19: Virtual Screening of the Potent Synthetic and Natural Compounds as.., Research Square, doi:10.21203/rs.3.rs-37994/v1 (Preprint)
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Silico study identifying kappa-carrageenan and other compounds as potential candidates for SARS-CoV-2 inhibition.
Sattari et al., 29 Jun 2020, preprint, 3 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperIota-carragee..All
Repositioning Therapeutics for COVID-19: Virtual Screening of the Potent Synthetic and Natural Compounds as SARS-CoV-2 3CLpro Inhibitors
Ahmad Sattari, Ali Ramazani, Hamideh Aghahosseini
doi:10.21203/rs.3.rs-37994/v1
Today, nding potential therapeutics for COVID-19 caused by the widespread transmission of SARS-CoV-2 has become a global challenge. Molecular docking investigation of the therapeutic potential of marketed drugs is a fast and cost effective approach to provide a solution to this problem. In this study, docking simulations performed on the reported structure of the virus main protease, 3CLpro, to identify potential inhibitors. Accordingly, a database of 50 synthetic compounds including approved drugs and those undergoing clinical trials, and 40 natural compounds particularly those employed in traditional Iranian medicine was constructed. The results indicated that the anti-in ammatory drugs, Licofelone acyl glucuronide and delta-bilirubin, and natural compounds such as kappa-carrageenan conformer and beta-D-galactopyranosyl with minimal side-effects, according to in-vitro studies, are good candidates to block the enzymatic activity of SARS-CoV-2 3CLpro. Moreover, the compound 1 could be a potential drug candidate for COVID-19 due to its favorable interactions with the 3CLpro.
Supplementary Files This is a list of supplementary les associated with this preprint. Click to download. SupportingInformation.docx GraphicalAbstract.tif
References
Aa, Agrawal, Garron, Tao, Peng et al., Proc. Natl. Acad. Sci
Ad, Han, Penn-Nicholson, Cho, Ge et al., None, Virology
Ad, Hui, Azhar, Madani, Ntoumi et al., None, Int. J. Infect. Dis
Ad, Hui, Azhar, Madani, Ntoumi et al., WHO Statement Regarding Cluster of Pneumonia Cases in
Aj, Kahn, Mcintosh ; Geller, Varbanov, Duval, None, Pediatr. Infect. Dis. J
Aj. Cohen ; Zhou, Yang, Wang, Hu, Zhang et al., None, Nature
Alikhani, Razzaghi-Asl, Ramazani, Hosseinzadeh, None, J. Mol. Struct
Almeida, Berry, Cunningham, Hamre, Hofstad et al., None, Adv. Virus Res. (Elsevier)
Ameri, Heydarirad, Mahdavi, Jafari, Ghobadi et al., None, eM. Abolhassani, Arch. Med. Sci
Anand, Ziebuhr, Wadhwani, Mesters, Hilgenfeld, None, Science
Ar, Dizaji, Rezaie Kehkhaie, Taqi Khammar, Shirazinia, None, Int J Plant Sci Hor
Asadi-Samani, Moradi, Bahmani, Shahrani, None, Int.J. PharmTech Res
Ascone, Sakidja, None, Int. J. Comput Biol. Drug Des
Beck, Shin, Choi, Park, Kang, None, doi:10.1101/2020.01.31.929547
Bosch, Van Der Zee, De Haan, Rottier, None, J. Virol
Chang, Tung, Lee, Chen, Hsiao et al., None, doi:10.20944/preprints202002.0242.v1
Choubey, Varughese, Kumar, Beniwal, None, Pharm. Pat. Anal
Covid, Global Cases by Johns Hopkins CSSE. Вилучено з
Fehr, Perlman, Coronaviruses
Gaillard, None, J. Chem. Inf. Model
Gao, Tian, Yang, None, Biosci. Trends
Goldsmith, Tatti, Ksiazek, Rollin, Comer et al., None, Emerg. Infect. Dis
Grassauer, Eva, Us, None
Ji, Wang, Zhao, Zai, Li, None, J. Med. Virol
Johnson, Mesecar ; Kumar, Tan, Wang, Lin et al., None, Bioorg. Med. Chem. Lett
Liu, Zhang, Jin, Yang, Rao, The crystal structure of COVID-19 main protease in complex with an inhibitor N3, doi:10.2210/PDB6LU7/PDB
Lu, Mahindroo, Liang, Peng, Kuo et al., None, Acta Crystallogr., Sect. D: Biol. Crystallogr
Ma, Fu, Khojasteh, Dalvie, Zhang, None, J. Med. Chem
Masters, Eagon, Heying, None, J. Mol. Graph. Model
Morris, Huey, Lindstrom, Sanner, Belew et al., None, J. Comput. Chem
Naoi, Shamoto-Nagai, Maruyama, None, Future Neurol
Neuman, Adair, Yoshioka, Quispe, Orca et al., None, J. Virol
Neuman, Kiss, Kunding, Bhella, Baksh et al., None, J. Struct. Biol
Organization, Laboratory testing of human suspected cases of novel coronavirus ( nCoV) infection: interim guidance" can be found under www
Orita, Ohno, Warizaya, Amano, Niimi, None, Methods in enzymology
Pillaiyar, Manickam, Namasivayam, Hayashi, Jung ; Ba et al., None, J. Med. Chem
Price, Gould, Marsh, None, J. Chem. Educ
Shu, Mccauley, None, Euro Surveill
Trott, Olson, None, J. Comput. Chem
Wallace, Laskowski, Thornton, None, Protein Eng. Des. Sel
Wang, Chen, Lu, Chen, Zhang, None, Biosci. Trends
Winther, Hansen, Campbell-Tofte, None, Botanics
Wong, Li, Lau, Woo, None, Viruses
Wu, Liu, Yang, Zhang, Zhong et al., None, Acta Pharm. Sin. B
Yang, Yang, Ding, Liu, Lou et al., Proc. Natl. Acad. Sci
Zhu, Zhang, Wang, Li, Yang et al., None, N Engl. J. Med
Zhu, Zhang, Ye, Li, Zhou et al., None, Biol. Pharm. Bull
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit